Increased expression of heparanase in symptomatic carotid atherosclerosis

Atherosclerosis

Volumn 226, Issue 1, 2013, Pages 67-73

  osterholm C ^a   Folkersen, L ^a   Lengquist, M ^a   Ponten F ^b   Renne T ^a   Li, JP ^b   Hedin, U ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Atherosclerosis; Extracellular matrix; Heparan sulfate proteoglycans; Heparanase; Inflammation; Smooth muscle cell

Indexed keywords

CD137 ANTIGEN; CD28 ANTIGEN; CD86 ANTIGEN; HEPARAN SULFATE; HEPARANASE; INTERLEUKIN 18; INTERLEUKIN 1BETA; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; RANTES;

ADULT; ARTICLE; ATHEROSCLEROTIC PLAQUE; CAROTID ATHEROSCLEROSIS; CAROTID ENDARTERECTOMY; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFLAMMATORY CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOOTH MUSCLE FIBER; T LYMPHOCYTE; TISSUE MICROARRAY;

ADULT; CAROTID ARTERY DISEASES; GENE EXPRESSION REGULATION; GLUCURONIDASE; HUMANS; MIDDLE AGED;

EID: 84871384293     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.09.030     Document Type: Article

References (31)

1. Shah P.K. Inflammation and plaque vulnerability. Cardiovasc Drugs Ther 2009, 23:31-40.
2. Johnson J.L. Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability. Expert Rev Cardiovasc Ther 2007, 5:265-282.
3. Bishop J.R., Schuksz M., Esko J.D. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 2007, 446:1030-1037.
4. Stanford K.I., Bishop J.R., Foley E.M., et al. Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice. J Clin Invest 2009, 119:3236-3245.
5. Clowes A.W., Breslow J.L., Karnovsky M.J. Regression of myointimal thickening following carotid endothelial injury and development of aortic foam cell lesions in long term hypercholesterolemic rats. Lab Invest 1977, 36:73-81.
6. Bingley J.A., Hayward I.P., Campbell J.H., Campbell G.R. Arterial heparan sulfate proteoglycans inhibit vascular smooth muscle cell proliferation and phenotype change in vitro and neointimal formation in vivo. J Vasc Surg 1998, 28:308-318.
7. Tran-Lundmark K., Tran P.K., Paulsson-Berne G., et al. Heparan sulfate in perlecan promotes mouse atherosclerosis: roles in lipid permeability, lipid retention, and smooth muscle cell proliferation. Circ Res 2008, 103:43-52.
8. Tran P.K., Agardh H.E., Tran-Lundmark K., et al. Reduced perlecan expression and accumulation in human carotid atherosclerotic lesions. Atherosclerosis 2007, 190:264-270.
9. Lindahl U., Li J.P. Interactions between heparan sulfate and proteins-design and functional implications. Int Rev Cell Mol Biol 2009, 276:105-159.
10. Vlodavsky I., Friedmann Y., Elkin M., et al. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med 1999, 5:793-802.
11. Vlodavsky I., Beckhove P., Lerner I., et al. Significance of heparanase in cancer and inflammation. Cancer Microenviron 2012, 5:115-132.
12. Baker A.B., Groothuis A., Jonas M., et al. Heparanase alters arterial structure, mechanics, and repair following endovascular stenting in mice. Circ Res 2009, 104:380-387.
13. Myler H.A., Lipke E.A., Rice E.E., West J.L. Novel heparanase-inhibiting antibody reduces neointima formation. J Biochem 2006, 139:339-345.
14. Razuvaev A., Ekstrand J., Folkersen L., et al. Correlations between clinical variables and gene-expression profiles in carotid plaque instability. Eur J Vasc Endovasc Surg 2011, 42:722-730.
15. Ponten F., Schwenk J.M., Asplund A., Edqvist P.H. The human protein atlas as a proteomic resource for biomarker discovery. J Intern Med 2011, 270:428-446.
16. Kleinschnitz C., Stoll G., Bendszus M., et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 2006, 203:513-518.
17. Ostrovsky O., Korostishevsky M., Shafat I., et al. Inverse correlation between HPSE gene single nucleotide polymorphisms and heparanase expression: possibility of multiple levels of heparanase regulation. J Leukoc Biol 2009, 86:445-455.
18. Nadir Y., Brenner B. Heparanase procoagulant effects and inhibition by heparins. Thromb Res 2010, 125(Suppl. 2):S72-S76.
19. Baker A.B., Gibson W.J., Kolachalama V.B., et al. Heparanase regulates thrombosis in vascular injury and stent-induced flow disturbance. J Am Coll Cardiol 2012, 59:1551-1560.
20. Rao G., Ding H.G., Huang W., et al. Reactive oxygen species mediate high glucose-induced heparanase-1 production and heparan sulphate proteoglycan degradation in human and rat endothelial cells: a potential role in the pathogenesis of atherosclerosis. Diabetologia 2011, 54:1527-1538.
21. Fitzgerald M., Hayward I.P., Thomas A.C., Campbell G.R., Campbell J.H. Matrix metalloproteinase can facilitate the heparanase-induced promotion of phenotype change in vascular smooth muscle cells. Atherosclerosis 1999, 145:97-106.
22. Baker A.B., Chatzizisis Y.S., Beigel R., et al. Regulation of heparanase expression in coronary artery disease in diabetic, hyperlipidemic swine. Atherosclerosis 2010, 213:436-442.
23. Chen G., Wang D., Vikramadithyan R., et al. Inflammatory cytokines and fatty acids regulate endothelial cell heparanase expression. Biochemistry 2004, 43:4971-4977.
24. Escobar Galvis M.L., Jia J., Zhang X., et al. Transgenic or tumor-induced expression of heparanase upregulates sulfation of heparan sulfate. Nat Chem Biol 2007, 3:773-778.
25. Li W., Kornmark L., Jonasson L., Forssell C., Yuan X.M. Cathepsin L is significantly associated with apoptosis and plaque destabilization in human atherosclerosis. Atherosclerosis 2009, 202:92-102.
26. Abboud-Jarrous G., Atzmon R., Peretz T., et al. Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment. J Biol Chem 2008, 283:18167-18176.
27. Gilat D., Hershkoviz R., Goldkorn I., et al. Molecular behavior adapts to context: heparanase functions as an extracellular matrix-degrading enzyme or as a T cell adhesion molecule, depending on the local pH. J Exp Med 1995, 181:1929-1934.
28. Bitan M., Weiss L., Reibstein I., et al. Heparanase upregulates Th2 cytokines, ameliorating experimental autoimmune encephalitis. Mol Immunol 2010, 47:1890-1898.
29. Smith E.B., Thompson W.D. Fibrin as a factor in atherogenesis. Thromb Res 1994, 73:1-19.
30. Borissoff J.I., Heeneman S., Kilinc E., et al. Early atherosclerosis exhibits an enhanced procoagulant state. Circulation 2010, 122:821-830.
31. Lepedda A.J., Cigliano A., Cherchi G.M., et al. A proteomic approach to differentiate histologically classified stable and unstable plaques from human carotid arteries. Atherosclerosis 2009, 203:112-118.